Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 14/20 | 0.68 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.62 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184716 | 0.89 | WNT3A (0.65) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2183208 | 0.87 | WNT3A (0.67) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2182842 | 0.85 | WNT3A (0.93) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2184045 | 0.84 | WNT3A (0.80) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2184677 | 0.84 | PSEN1 (0.72) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2182471 | 0.84 | WNT3A (0.62) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492794 | 0.82 | PPIA (0.58) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2182327 | 0.81 | WNT3A (1.00) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1723593 | 0.81 | WNT3A (1.00) | WNT3APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2185880 | 0.81 | WNT3A (0.69) | WNT3APSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | WNT3A 1903/4885PSEN1 3/4885PSEN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.